Essentials of Model-informed Drug Development in Oncology Blog Post
Model-informed drug development in oncology is critical to developing safer and more effective cancer drugs. Read the blog to learn more…
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug Blog Post
Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to select a higher starting dose that would lower costs and reduce cycle times RADNOR, PA…
What Are SDTM Supplemental Qualifiers? Blog Post
We touched on the SDTM supplemental qualifier in the SDTM mapping process simplified. In this blog, we’ll delve deeper into this subject with detailed examples. So, what are SDTM supplemental…
Using Virtual Twin Technology to Predict Drug Exposure in Individual Patients Blog Post
In this webinar, Dr. Tom Polasek, a clinical pharmacologist at Certara Strategic Consulting, explained how he used the Simcyp Simulator to predict olanzapine exposure in individual patients. By watching this webinar you will learn how PBPK modeling and simulation technology can be re-purposed to support model-informed precision dosing.
